Fig. 3
From: Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China
Kaplan–Meier survival curves of data obtained from symptom onset. We have divided the hATTR patients into two groups: Gly83Arg and non-Gly83Arg. The total mortality of non-Gly83Arg was 45.5% and the median survival time from symptom onset was 7.5 (IQR: 5.3) years. The evidence showed a clear better survival in patients with Gly83Arg mutation (log Rank (Mantel-Cox), χ2 = 24.383, P < 0.001)